Aveo Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Aveo Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-878	Closed	-$354K	–	342
2024 Q4	$354K	Sell	878 -198	-18%	-$91.8K	0.04%	258
2024 Q3	$500K	Sell	1,076 -37	-3%	-$17.8K	0.05%	199
2024 Q2	$522K	Sell	1,113 -35	-3%	-$15.2K	0.06%	184
2024 Q1	$460K	Buy	1,148 +72	+7%	+$30.4K	0.05%	229
2023 Q4	$438K	Buy	1,076 +469	+77%	+$173K	0.05%	220
2023 Q3	$211K	Sell	607 -11	-2%	-$3.85K	0.03%	314
2023 Q2	$217K	Buy	+618	New	+$208K	0.03%	317
2023 Q1	–	Sell	-1,216	Closed	-$351K	–	372
2022 Q4	$351K	Buy	1,216 +330	+37%	+$101K	0.05%	239
2022 Q3	$257K	Buy	+886	New	+$255K	0.04%	234

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Aveo Capital Partners's VRTX Position: Q1 2025 in Review

Aveo Capital Partners sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 878 shares — an estimated $354K sold.

Aveo Capital Partners first reported a position in VRTX in Q3 2022 and held it in 9 quarters. The position peaked at $522K in Q2 2024. 1,613 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

Aveo Capital Partners reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Aveo Capital Partners sold 878 Vertex Pharmaceuticals shares in Q1 2025, an estimated $354K.
Aveo Capital Partners first reported a position in Vertex Pharmaceuticals in Q3 2022 and held it in 9 quarters.
Aveo Capital Partners's Vertex Pharmaceuticals position peaked at $522K in Q2 2024.
1,613 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Aveo Capital Partners's 13F filing for Q1 2025, filed 12 May 2025.